The estimated Net Worth of Alexander J Denner is at least $3.07 milliard dollars as of 26 February 2021. Alexander Denner owns over 1,350,000 units of Biogen Inc stock worth over $3,063,995,100 and over the last 15 years he sold BIIB stock worth over $1,800,788. In addition, he makes $422,643 as Independent Director at Biogen Inc.
Alexander has made over 23 trades of the Biogen Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 1,350,000 units of BIIB stock worth $12,744,000 on 26 February 2021.
The largest trade he's ever made was buying 1,350,000 units of Biogen Inc stock on 26 February 2021 worth over $12,744,000. On average, Alexander trades about 108,423 units every 53 days since 2009. As of 26 February 2021 he still owns at least 15,390,000 units of Biogen Inc stock.
You can see the complete history of Alexander Denner stock trades at the bottom of the page.
Dr. Alexander J. Denner, Ph.D. is an Independent Director of Biogen Inc. Dr. Denner is a founding partner and Chief Investment Officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance stockholder value. From 2006 to 2011 Dr. Denner served as a Senior Managing Director at Icahn Capital L.P. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. Dr. Denner also serves as a director of The Medicines Company, a biopharmaceutical company, where he is Chairman of the Board.
As the Independent Director of Biogen Inc, the total compensation of Alexander Denner at Biogen Inc is $422,643. There are 12 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Alexander Denner is 49, he's been the Independent Director of Biogen Inc since 2009. There are 23 older and 1 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Alexander's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner et Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: